LANGERHANS CELL HISTIOCYTOSIS (LCH)
Clinical trials for LANGERHANS CELL HISTIOCYTOSIS (LCH) explained in plain language.
Never miss a new study
Get alerted when new LANGERHANS CELL HISTIOCYTOSIS (LCH) trials appear
Sign up with your email to follow new studies for LANGERHANS CELL HISTIOCYTOSIS (LCH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Old drug, new hope: lenalidomide takes on rare histiocyte disorders
Disease control OngoingThis study tests the chemotherapy drug lenalidomide in 12 adults with one of three rare diseases where immune cells grow out of control: Langerhans cell histiocytosis, Erdheim-Chester disease, or histiocytic sarcoma. The main goal is to see how many people have their disease shri…
Matched conditions: LANGERHANS CELL HISTIOCYTOSIS (LCH)
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 17, 2026 05:21 UTC
-
New hope for rare blood disease: drug cocktail targets stubborn cases
Disease control OngoingThis study tests a three-drug combination (selinexor, thalidomide, and dexamethasone) in 40 adults with Langerhans cell histiocytosis that did not improve or came back after standard treatment. The goal is to see if the regimen can control the disease and delay progression. Parti…
Matched conditions: LANGERHANS CELL HISTIOCYTOSIS (LCH)
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Scientists hunt for genetic clues in rare blood disorders
Knowledge-focused TerminatedThis study looks at the DNA of people with rare blood diseases like Castleman disease and histiocytosis. The goal is to find genetic changes that could be targeted with existing or new treatments. About 135 participants will provide samples for genetic testing. The study is curre…
Matched conditions: LANGERHANS CELL HISTIOCYTOSIS (LCH)
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC